NEW YORK – Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services.
Ann Arbor, Michigan-based Genomenon said today that the new partnership will allow the company to bring its Mastermind genomic search engine to clinical laboratories in China.
"Our partnership with Shanghai Shanyi will allow us to expand our footprint in the China market, seamlessly integrating with their other best-of-breed end-to-end clinical [next-generation sequencing] solutions," Genomenon CEO Mike Klein said in a statement.
"We’re proud to bring Mastermind to clinical laboratories in China," added Lei Li, general manager of Shanghai Shanyi. Shanyi said that early work with Genomenon has helped customers reduce the amount of time they spend searching for variants of unknown significance by 60 percent to 80 percent.
Genomenon previously operated only in North America and Europe, through partnerships with the likes of US-based LifeMap Sciences, Parabricks, Belgian artificial intelligence vendor Diploid, and others.
The company raised $2.5 million in private equity early this year.